Skip to content
homeHOME R&D Mission & Vison R&D Pipeline

R&D Pipeline

YRI enhances success rates and maintains an innovative drug pipeline by adopting a strategy that focuses on critical areas of unmet medical need. Currently, the main areas of focus include cardiovascular and metabolic diseases, inflammatory and immune disorders, and cancer. YRI continually enriches its competitive drug pipeline by establishing collaborative partnerships with academic research centers, bio-ventures, and government-funded research institutes worldwide. A strong development pipeline further strengthens YRI’s global outreach capacity by expanding potential licensing agreements.

Gastrointestinal Disorder

Gastrointestinal Disorder
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH12852 Postoperative ileus
Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2

Cardiometabolic Disorder

Cardiometabolic Disorder
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YHP1604 Hypertension/Dyslipidemia
Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3
YHP1701 Hypertension/Dyslipidemia
Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3
YH14755 Dyslipidemia/Diabetes
Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3
YH22162 Hypertension
Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3
YH25724 NASH/Obesity
PreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinical
YH26136 Dyslipidemia/Thrombosis
PreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinical
YH-NCE5 NASH
DiscoveryDiscoveryDiscoveryDiscoveryDiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE6 NASH
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery

Immunology / Inflammation

Immunology / Inflammation
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH23537 Peridontitis/Arthritis
Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2
YH26153 Peri-implantitis
Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1
YH-NCE1 Asthma
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-siRNA1 Keloid
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery

Oncology

Oncology
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YH25448 Cancer
Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1Phase 1
YH24931 Cancer
PreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinicalPreclinical
YH-NCE2 Liver cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE3 Lung cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE4 Cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-NCE7 Cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO1 Cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO2 Cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-BIO3 Cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery
YH-siRNA2 Liver cancer
DiscoveryDiscoveryDiscoveryDiscoveryDiscovery

Others

Others
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
YHD1119 Neuropathic pain
Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3